SG Americas Securities LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 101.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 101,280 shares of the medical research company’s stock after buying an additional 51,074 shares during the quarter. SG Americas Securities LLC’s holdings in IQVIA were worth $17,272,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the stock. Smith Salley Wealth Management raised its holdings in shares of IQVIA by 0.5% during the first quarter. Smith Salley Wealth Management now owns 12,987 shares of the medical research company’s stock worth $2,215,000 after acquiring an additional 71 shares during the period. World Investment Advisors increased its holdings in IQVIA by 1.4% during the 4th quarter. World Investment Advisors now owns 81,682 shares of the medical research company’s stock worth $18,412,000 after purchasing an additional 1,162 shares in the last quarter. Farmers National Bank acquired a new stake in shares of IQVIA in the 4th quarter valued at about $236,000. Eos Management L.P. bought a new stake in shares of IQVIA in the fourth quarter valued at about $965,000. Finally, Corient Private Wealth LLC lifted its holdings in shares of IQVIA by 18.4% in the fourth quarter. Corient Private Wealth LLC now owns 15,358 shares of the medical research company’s stock valued at $3,462,000 after purchasing an additional 2,383 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.
Analyst Ratings Changes
A number of research firms recently issued reports on IQV. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a report on Friday, March 6th. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Finally, Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $222.56.
IQVIA Stock Performance
IQV opened at $186.30 on Friday. The business’s 50-day simple moving average is $174.17 and its 200 day simple moving average is $190.06. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $31.09 billion, a PE ratio of 23.09, a PEG ratio of 1.59 and a beta of 1.21.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the firm earned $2.70 EPS. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.
IQVIA announced that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its stock is undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Further Reading
- Five stocks we like better than IQVIA
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
